Liz Rosethorne

Sygnature Discovery

Elizabeth Rosethorne is a cellular and molecular pharmacologist with extensive experience in GPCR pharmacology and Respiratory Drug Discovery within industry and academia. Her expertise predominantly lies in developing and utilizing a wide range of in vitro experimental techniques for use in screening novel compounds and mechanism of action studies. These include the use of phenotypic assays to identify novel targets for disease, the exploration of biased signalling and the role of signalling kinetics in determining agonist efficacy.

Liz gained a PhD in GPCR Pharmacology at the University of Leicester, after which she was an Investigator at the Novartis Institutes for Biomedical Research. Here she managed a small team focused on primary human cell biology and High Content Imaging, with a focus on chronic respiratory diseases. She then moved to the University of Nottingham as a Senior Research Fellow in the School of Life Sciences, where she continued to focus on cAMP signalling and its role in inhibiting the chronic phenotypic behaviours associated with idiopathic pulmonary fibrosis (IPF). Liz currently works for Sygnature Discovery, where she continues to work and consult on a range of pre-clinical drug discovery programmes.